Acquisition of Sekisui Virotech GmbH led by the VIROTECH Diagnostics Holding GmbH alongside with Dr. Klaus Ackermann -- MEDICA Trade Fair

27/09/2017

VIROTECH Diagnostics GmbH

Acquisition of Sekisui Virotech GmbH led by the VIROTECH Diagnostics Holding GmbH alongside with Dr. Klaus Ackermann

Rüsselsheim, 11/11/2016: VIROTECH Diagnostics Holding GmbH and Dr. Klaus Ackermann jointly acquire the whole operating business of Sekisui Virotech GmbH via a stock purchase. Confidentiality has been stipulated with regard to the purchasing price.

A Munich-based family office backing the VIROTECH Diagnostics Holding GmbH and Dr. Klaus Ackermann acquire the entire operating business of Sekisui Virotech GmbH. The acquisition of the business is fully financed with equity. No outside debt was used in the course of the transaction. Going forward, the company will be operating under the name VIROTECH Diagnostics GmbH and continues to be headquartered in Rüsselheim, Germany with its roughly 90 employees.

Founded in 1986 under the name Virotech Systemdiagnostika, the company emerged over the last 30 years as an expert for ELISA and LINE tests. Today the company generates a turnover of about 11 million Euro with the production and distribution of diagnostics products to more than 30 countries worldwide.

As Virotech was over the last years’ part of larger conglomerates such as the Genzyme Corporation in 1993-2011 and of Sekisui Chemical in 2011-2016, the acquisition now offers the return to privately owned independence. The VIROTECH Diagnostics Holding GmbH and Dr. Klaus Ackermann jointly pursue the long-term goal of re-establishing VIROTECH as an independent, sustainable and successful diagnostic company. In order to do so, the new owners have no time limitations to their shareholding.

To improve production workflows and product quality the new shareholders have already provided additional equity for purchasing a more efficient filling system and a new coating machine. In the coming years, VIROTECH will focus on its core – continuously improving the existing ELISA and LINE test portfolio. In addition, the company will allocate resources towards expanding today’s product portfolio and adopting the existing tests to the ongoing automatization in modern laboratory operations. In order to further develop the business going forward, the new shareholders will be looking into finding new commercial real estate appropriate for a producing diagnostics business.

Exhibitor Data Sheet